Theriva Biologics, Inc.
TOVX NYSE
SEC CIK 894158
Follow Theriva Biologics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$1.5M
+66.3% vs same quarter last year
EPS, diluted
−$0.03
+93.3% vs same quarter last year
Operating cash flow
−$2.9M
+33.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$23.7M |
| FY24 | −$25.7M |
| FY23 | −$18.3M |
| FY22 | −$19.7M |
| FY21 | −$14.3M |
| FY20 | −$10M |
| FY19 | −$15.3M |
| FY18 | −$13.4M |
| FY17 | −$15.2M |
| FY16 | −$27.3M |
| FY15 | −$43.7M |
| FY14 | −$19.8M |
| FY13 | −$12.3M |
| FY12 | −$17.1M |
| FY11 | −$8.1M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$16.7M |
| FY24 | −$16.9M |
| FY23 | −$19.2M |
| FY22 | −$19.2M |
| FY21 | −$12.9M |
| FY20 | −$12.2M |
| FY19 | −$13.9M |
| FY18 | −$17.3M |
| FY17 | −$20.4M |
| FY16 | −$28.5M |
| FY15 | −$39.4M |
| FY14 | −$16.1M |
| FY13 | −$7.8M |
| FY12 | −$8.9M |
| FY11 | −$2.9M |